J.P. Marvel Investment Advisors LLC lessened its holdings in Charles River Laboratories International, Inc. (NYSE:CRL) by 0.1% in the 2nd quarter, according to its most recent filing with the SEC. The firm owned 15,770 shares of the medical research company’s stock after selling 20 shares during the period. J.P. Marvel Investment Advisors LLC’s holdings in Charles River Laboratories International were worth $1,595,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also made changes to their positions in the company. Zurcher Kantonalbank Zurich Cantonalbank lifted its position in Charles River Laboratories International by 12.7% during the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,791 shares of the medical research company’s stock valued at $181,000 after acquiring an additional 202 shares during the last quarter. Riverhead Capital Management LLC lifted its position in Charles River Laboratories International by 14.7% during the second quarter. Riverhead Capital Management LLC now owns 1,931 shares of the medical research company’s stock valued at $195,000 after acquiring an additional 247 shares during the last quarter. Cambridge Advisors Inc. purchased a new stake in Charles River Laboratories International during the second quarter valued at approximately $202,000. Advisor Partners LLC purchased a new stake in Charles River Laboratories International during the second quarter valued at approximately $208,000. Finally, Campbell & CO Investment Adviser LLC purchased a new stake in Charles River Laboratories International during the second quarter valued at approximately $217,000. 95.08% of the stock is owned by hedge funds and other institutional investors.

WARNING: “J.P. Marvel Investment Advisors LLC Lowers Stake in Charles River Laboratories International, Inc. (CRL)” was originally published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this article on another domain, it was illegally copied and republished in violation of U.S. and international trademark and copyright law. The legal version of this article can be viewed at https://www.thecerbatgem.com/2017/10/16/j-p-marvel-investment-advisors-llc-lowers-stake-in-charles-river-laboratories-international-inc-crl.html.

In other news, insider William D. Barbo sold 4,000 shares of the business’s stock in a transaction that occurred on Thursday, August 17th. The shares were sold at an average price of $99.91, for a total transaction of $399,640.00. Following the completion of the sale, the insider now owns 20,424 shares in the company, valued at approximately $2,040,561.84. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider David Ross Smith sold 2,552 shares of the business’s stock in a transaction that occurred on Monday, August 14th. The stock was sold at an average price of $67.10, for a total transaction of $171,239.20. Following the sale, the insider now owns 11,671 shares of the company’s stock, valued at approximately $783,124.10. The disclosure for this sale can be found here. Insiders have sold a total of 18,699 shares of company stock valued at $1,892,393 in the last 90 days. Insiders own 2.20% of the company’s stock.

A number of equities research analysts recently commented on CRL shares. Jefferies Group LLC reissued a “buy” rating and set a $120.00 target price on shares of Charles River Laboratories International in a research report on Tuesday, September 12th. Zacks Investment Research raised shares of Charles River Laboratories International from a “hold” rating to a “buy” rating and set a $110.00 target price for the company in a research report on Thursday, August 10th. Royal Bank Of Canada started coverage on shares of Charles River Laboratories International in a research report on Tuesday, September 19th. They set a “sector perform” rating and a $110.00 target price for the company. BidaskClub raised shares of Charles River Laboratories International from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, August 22nd. Finally, Robert W. Baird reissued a “buy” rating and set a $114.00 target price on shares of Charles River Laboratories International in a research report on Friday, September 1st. Six analysts have rated the stock with a hold rating, four have assigned a buy rating and one has given a strong buy rating to the stock. The stock has an average rating of “Buy” and an average target price of $102.05.

Shares of Charles River Laboratories International, Inc. (NYSE CRL) traded up 1.041% on Monday, reaching $114.095. 139,653 shares of the company’s stock were exchanged. Charles River Laboratories International, Inc. has a one year low of $67.20 and a one year high of $114.61. The firm has a 50 day moving average of $108.17 and a 200 day moving average of $98.26. The firm has a market capitalization of $5.43 billion, a P/E ratio of 30.065 and a beta of 0.96.

Charles River Laboratories International (NYSE:CRL) last issued its quarterly earnings data on Wednesday, August 9th. The medical research company reported $1.29 earnings per share for the quarter, topping the consensus estimate of $1.22 by $0.07. The business had revenue of $469.13 million during the quarter, compared to the consensus estimate of $458.25 million. Charles River Laboratories International had a net margin of 10.13% and a return on equity of 27.02%. The company’s revenue was up 8.1% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $1.20 EPS. On average, equities research analysts predict that Charles River Laboratories International, Inc. will post $5.10 EPS for the current year.

About Charles River Laboratories International

Charles River Laboratories International, Inc is an early-stage contract research company. The Company is engaged in laboratory animal medicine and science (research model technologies) and develop a portfolio of discovery and safety assessment services, both good laboratory practice (GLP) and non-GLP, which supports its clients from target identification through non-clinical development.

Want to see what other hedge funds are holding CRL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Charles River Laboratories International, Inc. (NYSE:CRL).

Institutional Ownership by Quarter for Charles River Laboratories International (NYSE:CRL)

Receive News & Stock Ratings for Charles River Laboratories International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories International Inc. and related stocks with our FREE daily email newsletter.